评估 HPV 疫苗在口腔疾病患者和非口腔疾病患者中的流行程度和潜在影响:十年回顾性研究

IF 4.7 3区 医学 Q1 MEDICINE, RESEARCH & EXPERIMENTAL
Michela Buttà , Nicola Serra , Erika Mannino , Vera Panzarella , Daniela Cabibi , Giuseppina Campisi , Daniela Pistoia , Giuseppina Capra
{"title":"评估 HPV 疫苗在口腔疾病患者和非口腔疾病患者中的流行程度和潜在影响:十年回顾性研究","authors":"Michela Buttà ,&nbsp;Nicola Serra ,&nbsp;Erika Mannino ,&nbsp;Vera Panzarella ,&nbsp;Daniela Cabibi ,&nbsp;Giuseppina Campisi ,&nbsp;Daniela Pistoia ,&nbsp;Giuseppina Capra","doi":"10.1016/j.arcmed.2024.103059","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><p>The prevalence of oral human papillomavirus (HPV) in the healthy population and patients with oral diseases such as oral squamous cell carcinoma (OSCC), oral potentially malignant disorders (OPMDs), and oral benign lesions (BL), is not consistently described in the literature, with scarce and often heterogeneous data. In addition, the efficacy of HPV prophylactic vaccines in preventing HPV-related oral disorders has been scarcely investigated.</p></div><div><h3>Methods</h3><p>The prevalence of HPV and the potential impact of vaccines were analyzed in 1,415 oral rinse specimens, collected over 10 years and grouped into four categories based on histological/clinical diagnosis.</p></div><div><h3>Results</h3><p>HPV prevalence in OSCC, OPMD, and BL patients and in healthy individuals potentially exposed to HPV (HPE) was comparable (12.7 vs. 27.2% vs. 13.5 vs. 9%). Statistical analysis of the vaccine impact involved calculating high and low estimates and showed a significant difference only for the low effect. The nonavalent vaccine had higher low estimates than the bivalent vaccine in OSCC and HPE patients (29.6 vs. 51.9%, <em>p</em> &lt; 0.05; 18.2 vs. 42.4%, <em>p</em> &lt; 0.05), while for OPMD and BL, the frequency of bivalent low estimates was lower than that of quadrivalent and nonavalent (48.6 vs. 68.6%, <em>p</em> &lt; 0.05 and 48.6 vs. 77.1%, <em>p</em> &lt; 0.05; 23.9 vs. 50.7%, <em>p</em> &lt; 0.05, and 23.9 vs. 63.4%, <em>p</em> &lt; 0.05).</p></div><div><h3>Conclusions</h3><p>This study provided new insights into the prevalence of oral HPV and showed that the nonavalent vaccine may provide better protection than the other vaccines in the presence of an OSCC diagnosis. Conversely, the quadrivalent vaccine may be sufficient to prevent OPMD and BL.</p></div>","PeriodicalId":8318,"journal":{"name":"Archives of Medical Research","volume":null,"pages":null},"PeriodicalIF":4.7000,"publicationDate":"2024-09-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0188440924001115/pdfft?md5=724d759997e58d4ca45656042270244b&pid=1-s2.0-S0188440924001115-main.pdf","citationCount":"0","resultStr":"{\"title\":\"Evaluation of the Prevalence and Potential Impact of HPV Vaccines in Patients with and Without Oral Diseases: A Ten-Year Retrospective Study\",\"authors\":\"Michela Buttà ,&nbsp;Nicola Serra ,&nbsp;Erika Mannino ,&nbsp;Vera Panzarella ,&nbsp;Daniela Cabibi ,&nbsp;Giuseppina Campisi ,&nbsp;Daniela Pistoia ,&nbsp;Giuseppina Capra\",\"doi\":\"10.1016/j.arcmed.2024.103059\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Background</h3><p>The prevalence of oral human papillomavirus (HPV) in the healthy population and patients with oral diseases such as oral squamous cell carcinoma (OSCC), oral potentially malignant disorders (OPMDs), and oral benign lesions (BL), is not consistently described in the literature, with scarce and often heterogeneous data. In addition, the efficacy of HPV prophylactic vaccines in preventing HPV-related oral disorders has been scarcely investigated.</p></div><div><h3>Methods</h3><p>The prevalence of HPV and the potential impact of vaccines were analyzed in 1,415 oral rinse specimens, collected over 10 years and grouped into four categories based on histological/clinical diagnosis.</p></div><div><h3>Results</h3><p>HPV prevalence in OSCC, OPMD, and BL patients and in healthy individuals potentially exposed to HPV (HPE) was comparable (12.7 vs. 27.2% vs. 13.5 vs. 9%). Statistical analysis of the vaccine impact involved calculating high and low estimates and showed a significant difference only for the low effect. The nonavalent vaccine had higher low estimates than the bivalent vaccine in OSCC and HPE patients (29.6 vs. 51.9%, <em>p</em> &lt; 0.05; 18.2 vs. 42.4%, <em>p</em> &lt; 0.05), while for OPMD and BL, the frequency of bivalent low estimates was lower than that of quadrivalent and nonavalent (48.6 vs. 68.6%, <em>p</em> &lt; 0.05 and 48.6 vs. 77.1%, <em>p</em> &lt; 0.05; 23.9 vs. 50.7%, <em>p</em> &lt; 0.05, and 23.9 vs. 63.4%, <em>p</em> &lt; 0.05).</p></div><div><h3>Conclusions</h3><p>This study provided new insights into the prevalence of oral HPV and showed that the nonavalent vaccine may provide better protection than the other vaccines in the presence of an OSCC diagnosis. Conversely, the quadrivalent vaccine may be sufficient to prevent OPMD and BL.</p></div>\",\"PeriodicalId\":8318,\"journal\":{\"name\":\"Archives of Medical Research\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":4.7000,\"publicationDate\":\"2024-09-05\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.sciencedirect.com/science/article/pii/S0188440924001115/pdfft?md5=724d759997e58d4ca45656042270244b&pid=1-s2.0-S0188440924001115-main.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Archives of Medical Research\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S0188440924001115\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"MEDICINE, RESEARCH & EXPERIMENTAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Archives of Medical Research","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0188440924001115","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}
引用次数: 0

摘要

背景:健康人群和口腔疾病患者(如口腔鳞状细胞癌(OSCC)、口腔潜在恶性疾病(OPMDs)和口腔良性病变(BL))中口腔人类乳头瘤病毒(HPV)的流行情况在文献中的描述并不一致,数据稀少且往往存在异质性。此外,HPV 预防性疫苗在预防 HPV 相关口腔疾病方面的功效也鲜有研究:方法:分析了 10 年来收集的 1,415 份口腔漱口液标本中的 HPV 感染率和疫苗的潜在影响,并根据组织学/临床诊断将标本分为四类:结果:OSCC、OPMD 和 BL 患者的 HPV 感染率与可能感染 HPV 的健康人 (HPE) 的感染率相当(12.7% vs. 27.2% vs. 13.5% vs. 9%)。对疫苗影响的统计分析包括计算高值和低值估计值,结果显示只有低值影响有显著差异。在 OSCC 和 HPE 患者中,无病毒疫苗的低估计值高于二价疫苗(29.6 vs. 51.9%,p < 0.05;18.2 vs. 42.4%,p < 0.05),而对于OPMD和BL,二价低估计值的频率低于四价和非二价(48.6 vs. 68.6%,p < 0.05和48.6 vs. 77.1%,p < 0.05;23.9 vs. 50.7%,p < 0.05和23.9 vs. 63.4%,p < 0.05):这项研究为了解口腔 HPV 的流行情况提供了新的视角,并表明在确诊 OSCC 的情况下,无价疫苗可能比其他疫苗提供更好的保护。相反,四价疫苗可能足以预防OPMD和BL。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Evaluation of the Prevalence and Potential Impact of HPV Vaccines in Patients with and Without Oral Diseases: A Ten-Year Retrospective Study

Background

The prevalence of oral human papillomavirus (HPV) in the healthy population and patients with oral diseases such as oral squamous cell carcinoma (OSCC), oral potentially malignant disorders (OPMDs), and oral benign lesions (BL), is not consistently described in the literature, with scarce and often heterogeneous data. In addition, the efficacy of HPV prophylactic vaccines in preventing HPV-related oral disorders has been scarcely investigated.

Methods

The prevalence of HPV and the potential impact of vaccines were analyzed in 1,415 oral rinse specimens, collected over 10 years and grouped into four categories based on histological/clinical diagnosis.

Results

HPV prevalence in OSCC, OPMD, and BL patients and in healthy individuals potentially exposed to HPV (HPE) was comparable (12.7 vs. 27.2% vs. 13.5 vs. 9%). Statistical analysis of the vaccine impact involved calculating high and low estimates and showed a significant difference only for the low effect. The nonavalent vaccine had higher low estimates than the bivalent vaccine in OSCC and HPE patients (29.6 vs. 51.9%, p < 0.05; 18.2 vs. 42.4%, p < 0.05), while for OPMD and BL, the frequency of bivalent low estimates was lower than that of quadrivalent and nonavalent (48.6 vs. 68.6%, p < 0.05 and 48.6 vs. 77.1%, p < 0.05; 23.9 vs. 50.7%, p < 0.05, and 23.9 vs. 63.4%, p < 0.05).

Conclusions

This study provided new insights into the prevalence of oral HPV and showed that the nonavalent vaccine may provide better protection than the other vaccines in the presence of an OSCC diagnosis. Conversely, the quadrivalent vaccine may be sufficient to prevent OPMD and BL.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Archives of Medical Research
Archives of Medical Research 医学-医学:研究与实验
CiteScore
12.50
自引率
0.00%
发文量
84
审稿时长
28 days
期刊介绍: Archives of Medical Research serves as a platform for publishing original peer-reviewed medical research, aiming to bridge gaps created by medical specialization. The journal covers three main categories - biomedical, clinical, and epidemiological contributions, along with review articles and preliminary communications. With an international scope, it presents the study of diseases from diverse perspectives, offering the medical community original investigations ranging from molecular biology to clinical epidemiology in a single publication.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信